Aktieanalys

Moberg Pharma: New Terbinafinee supplier has been submitted - Redeye

Redeye Publicerad: 08 Apr 09:10

Redeye views the news from Moberg Pharma that they have submitted an additional Terbinafine supplier to the company’s registration dossier as positive as it comes early in 2024. This process will most likely be concluded by the end of the year. This step is essential to secure a long-term supply of Terbinafine. This move is imperative to launch in more countries in the future. This does not change the timetable for the launches going forward but indicates that the timetable for the pan-European launch is on track.

Länk till analysen i sin helhet: https://www.redeye.se/research/994279/moberg-pharma-new-terbinafinee-supplier-has-been-submitted?utm_source=finwire&utm_medium=RSS

Nyheter om Moberg Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!